吡非尼酮治疗特发性肺纤维化的临床效果观察

目的探讨吡非尼酮治疗特发性肺纤维化的临床效果。方法本研究选取2016年8月-2018年5月丹东市某医院收治的60例特发性肺纤维化患者为研究对象。采用随机数字表法将患者分为对照组与观察组,每组30例。对照组患者给予醋酸泼尼松口服治疗,观察组患者在对照组治疗基础上服用吡非尼酮治疗。比较2组患者治疗前及治疗16周时的最大呼气流量(PEF)、第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、动脉血氧分压(PaO2)及白介素-6(IL-6)水平;比较治疗16周时2组患者的不良反应发生情况。结果治疗后,观察组患者PEF,FEV1及FVC分别为(3.58±0.22)L/s,(1.97±0.20)L及(1.99±0.10)L,大于对照组的(3.02±0.17)L/s,(1.77±0.23)L及(1.76±0.26)L,且2组患者PEF,FEV1及FVC均大于治疗前,差异均有统计学意义(P<0.05)。治疗后,观察组患者PaO2为(65.58±7.17)mmHg(1 mmHg=0.133 kPa),高于对照组的(59.49±6.84)mmHg,且2组患者PaO2均高于治疗前,差异均有统计学意义(P<0.05)。治疗后,观察组患者IL-6水平为(13.77±1.62)pg/mL,低于对照组的(15.30±1.53)pg/mL,且2组患者IL-6水平均低于治疗前,差异均有统计学意义(P<0.05)。2组患者不良反应发生率均较低,且差异无统计学意义(P>0.05)。结论采用吡非尼酮联合醋酸泼尼松治疗特发性肺纤维化的临床效果显著,其可有效改善患者的肺功能,降低IL-6水平,并提高PaO2水平,安全可靠,值得临床推广应用。

Clinical effect of pirfenidone in the treatment of idiopathic pulmonary fibrosis

Objective To explore the clinical effect of pirfenidone in the treatment of idiopathic pulmonary fibrosis.Methods Sixty patients with idiopathic pulmonary fibrosis admitted to a hospital in Dandong from August 2016 to May 2018 were selected as the research subjects.The patients were divided into a control group and an observation group using a random number table,with 30 cases in each group.Patients in the control group were treated with oral prednisone acetate,while patients in the observation group were given pirfenidone in addition.The peak expiratory flow(PEF),forced expiratory volume in 1 second(FEV1),forced vital capacity(FVC),partial pressure of oxygen(PaO2),levels of interleukin-6(IL-6)before treatment and at week 16 of treatment were compared between the two groups.The incidence of adverse reactions at week 16 of treatment was compared between the two groups.Results After treatment,the PEF,FEV1 and FVC of the observation group were(3.58±0.22)L/s,(1.97±0.20)L and(1.99±0.10)L,all significantly greater than those of the control group,which were(3.02±0.17)L/s,(1.77±0.23)L and(1.76±0.26)L,respectively,and the PEF,FEV1 and FVC of the two groups were significantly greater than before treatment(all P<0.05).After treatment,the PaO2 of the observation group was(65.58±7.17)mmHg(1 mmHg=0.133 kPa),significantly higher than(59.49±6.84)mmHg of the control group,and the PaO2 of both groups was higher than before treatment(all P<0.05).After treatment,the levels of IL-6 in the observation group were(13.77±1.62)pg/mL,significantly lower than those in the control group,which were(15.30±1.53)pg/mL,and the levels of IL-6 in the two groups were significantly lower than before treatment(P<0.05).The incidence of adverse reactions in both groups was low,and the difference was not statistically significant(P>0.05).Conclusion The clinical effect of pirfenidone combined with prednisone acetate in treating idiopathic pulmonary fibrosis is significant.It can effectively improve the lung function of patients,reduce the levels of IL-6 and increase the PaO2 level.It is safe,reliable,and worthy of wider clinical application.